Bone marrow transplantation (BMT) from an HLAmatched sibling donor (MSD) is the treatment of choice in young patients with severe aplastic anemia (SAA) and matched unrelated donor transplant is an option for patients without a MSD after failing immunosuppressive therapy (IST). Anecdotal data in patients with multiple myeloma (MM) and renal insufficiency suggest the feasibility of allografting, 1 the outcomes of BMT in patients with SAA with significant renal impairment are not known. Renal impairment resulting from drug toxicities may occur in patients with aplastic anemia (AA) treated with IST. The rarity of the disease, however, precludes the possibility of well-designed prospective studies in this patient population.
We identified three cases of SAA with significant renal impairment from databases of 77 consecutive patients who underwent BMT for acquired AA between 1996 and 2005 at two tertiary care centers: St George's Hospital, London, England (n ¼ 48) and Princess Margaret Hospital, Toronto, Canada (n ¼ 29). The characteristics and outcomes of these patients are summarized in Table 1 . Two patients had endstage renal impairment secondary to immunoglobulin (Ig) A nephropathy before the diagnosis of AA (patients 1 and 3). The other patient (patient 2) developed cyclosporineinduced nephrotoxicity related to prior IST.
Patient 1 was transplanted before the introduction of minimally intensive conditioning (MIC) protocols at our institutes. The combination of cyclophosphamide (CY) and antithymocyte globulin (ATG) is a standard preparative regimen for AA. 2 High-dose CY has been used successfully for autologous stem cell transplantation in MM with renal insufficiency, and in general, no dosage adjustment is suggested in the presence of renal failure. 3 It has been shown that clearance of CY is decreased in patients with renal impairment, resulting in increased systemic drug exposure, 4 and there have been case reports of fatal complications such as myopericarditis and prolonged myelosuppression. 5 Therefore, we modified the CY dose for creatinine clearance. Despite these modifications, this patient experienced significant regimen related toxicity (RRT) and died of multiorgan failure 7 months post-transplant, including severe rhabdomyolysis of uncertain cause.
We have previously reported the feasibility of successful donor engraftment in heavily pretreated patients with AA using a MIC regimen consisting of fludarabine, low-dose CY and alemtuzumab. 6 On the basis of these observations, we chose a MIC regimen and used alemtuzumab in the conditioning protocol for patients 2 and 3. Fludarabine dose was adjusted to 50% according to the creatinine clearance. No dose modifications are necessary for alemtuzumab in the presence of renal impairment; therefore, we used the dose according to the institutional protocols. To avoid further damage to compromised renal function, we used mycophenolate mofetil alone for graft-versus-host disease (GVHD) prophylaxis. Calcineurin inhibitors are well known to cause direct acute and chronic nephrotoxicity. A recent retrospective study demonstrated that longterm use of calcineurin inhibitor is independently associated with the development of chronic kidney disease following non-myeloablative hematopoietic cell transplantation. 7 Patients 2 and 3 did not develop any acute or chronic GVHD and were off all immunosuppressants by 12 and 9 months post-transplant, respectively. Patient 3 was also considered for renal transplantation from the same donor to take advantage of transplant tolerance. Unfortunately, her BMT donor was not deemed suitable for kidney donation owing to underlying hypertension. The patient has now started requiring regular dialysis support, 11 months post-transplant and 2 months after stopping all immunosuppressants.
The therapeutic goal of marrow transplantation in AA is sustained donor engraftment with minimal risk of RRT and GVHD. These cases demonstrate that with appropriate modifications of the conditioning regimen such as use of a MIC regimen and a calcineurin-free GVHD prophylaxis, BMT is feasible in patients with SAA with significant renal impairment.
We recognize that the intensity of the conditioning regimen may not be the only factor relating to the poor outcome of patient 1. He clearly had a more significant degree of renal impairment compared with patients 2 and 3, and was dialysis-dependent before transplantation. Such carefully selected patients may be candidates for combined kidney and marrow transplant approach as previously demonstrated by the Boston group. 1 Hamaki et al. IgA nephropathy. The conditioning regimen consisted of ATG, melphalan 60 mg/m 2 and total lymph node irradiation 4 Gy, and GVHD prophylaxis comprised cyclosporine and prednisolone. They demonstrated that the pharmacokinetic properties of melphalan were not altered on dialysis and concluded that this conditioning regimen may be another alternative to conventional CY and ATG in patients with renal impairment.
Interestingly, two out of our three cases, as well as the only other case of BMT for SAA with renal impairment published in the literature, involve renal impairment secondary to IgA nephropathy. Is this a chance association or is there an underlying autoimmune phenomenon linking AA and IgA nephropathy? There has been some suggestion that IgA nephropathy may represent a stem-cell disorder, and BMT has been shown to reverse the pathology of the disease in murine models. 9 On the basis of these observations, it was proposed that therapeutic effect of BMT may not only be related to donor cells replacing the recipient's immune cells, but also replenishing the damaged glomerular cells. 10 No improvement in renal function, however, was noted in our two patients with IgA nephropathy.
Our cases suggest that BMT in SAA patients with significant renal impairment may be feasible with acceptable toxicity using a MIC regimen. A potent GVHD preventative effect of alemtuzumab enabled us to use a calcineurin-free GVHD prophylaxis regimen and prevent further damage to the compromised renal function. These patients should not be denied the option of BMT, if clinically indicated. 
